title: Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.
abstract: We assessed the in vitro chemosensitivity of acute erythroblastic and megakaryoblastic leukemia cells from children with Down syndrome (DS) compared to non-DS children. We conducted in vitro tests using the MTT assay of bone marrow samples from 12 children with DS and 16 children without DS. Patients were newly diagnosed based on the morphology and expression of platelet-specific antigens. Induction failure occurred more frequently in the non-DS group (n = 4) than in the DS group (n = 0, P = .053). Children with DS had a superior event-free survival (EFS) probability of 0.750 at 4 years, compared to an EFS probability of 0.375 for non-DS children (P = .049). Blast cells from DS patients were significantly more sensitive to daunorubicin, melphalan, mitoxantrone, 4-hydroperoxy-cyclophosphamide, vincristine, etoposide, bleomycin, and pirarubicin than those from non-DS patients. Four of the 16 non-DS patients were found to have acquired an extra chromosome 21 in their leukemia cells: blasts from these patients also tended to have greater chemosensitivity than those from patients without an extra chromosome 21. Blast cells from DS patients are markedly sensitive to various drugs. These results suggest that the fragility of blast cells derived from DS patients may be related to an increased susceptibility to apoptosis.
authors.affiliation: Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Hongo
authors.forename: S
authors.initials: S
authors.lastname: Okada
authors.forename: C
authors.initials: C
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Fujii
authors.forename: H
authors.initials: H
authors.lastname: Hori
authors.forename: M
authors.initials: M
authors.lastname: Yazaki
authors.forename: R
authors.initials: R
authors.lastname: Hanada
authors.forename: Y
authors.initials: Y
authors.lastname: Horikoshi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D020732:Cytogenetic Analysis; D004314:Down Syndrome / Q000150:complications*; D018432:Drug Resistance, Multiple / Q000235:genetics; D005260:Female; D006801:Humans; D007223:Infant; D004915:Leukemia, Erythroblastic, Acute / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D007947:Leukemia, Megakaryoblastic, Acute / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex